This lecture is intended as a supplementary resource for clinicians and trainees to review evidence and discuss clinical cases.
What determines whether an antifungal will work?
This primer covers antifungal selection, administration, adverse effects, and monitoring. The resident section is designed for a 30-45 minute discussion, followed by additional pharmacology and evidence for fellows.
Resident core
Recognize the major coverage gaps, choose a formulation and route, identify toxicities, and arrange monitoring.
Fellow section
Interpret exposure and susceptibility together, distinguish CSF from brain tissue concentrations, and evaluate the evidence for newer agents.
Jump to fellow sectionWhich fungus is causing disease, and where? The answer depends on the specimen, the host, the severity of illness, and whether a collection or infected device remains. Prior antifungal exposure and interacting drugs can explain why an apparently appropriate agent fails. Candida from respiratory secretions usually represents colonization; a respiratory isolate alone does not establish invasive disease. [1]
A susceptible isolate may still require a different drug because of poor urine, CSF, or vitreous exposure. Abscesses and infected devices also require source control.
Antifungal classes and mechanisms
| Class | Target | Bedside implication |
|---|---|---|
| Triazoles | Inhibit fungal lanosterol 14-alpha-demethylase (CYP51), reducing ergosterol synthesis. | Spectrum and human CYP interactions differ substantially within the class. Fluconazole lacks Aspergillus and Mucorales activity. |
| Echinocandins | Inhibit beta-1,3-D-glucan synthase in the cell wall. | Active against many Candida species. Aspergillus activity does not make micafungin standard primary monotherapy for invasive aspergillosis. No useful Cryptococcus or Mucorales coverage. |
| Amphotericin B | Binds ergosterol and disrupts fungal membranes. | Broad yeast and mold activity, with clinically important resistant species. Formulation determines toxicity and distribution. |
| Flucytosine | Converted within fungal cells into metabolites that interfere with RNA and DNA synthesis. | Good CNS entry. Usually combined with another antifungal because resistance can emerge with monotherapy; selected symptomatic fluconazole-resistant C. glabrata urinary infections are an exception. [1] |
Coverage of echinocandins, polyenes, and flucytosine
| Class and example drug | Yeast role | Mold role | Coverage pitfall |
|---|---|---|---|
| Echinocandin: micafungin (Mycamine) | Initial Candida treatment, including many azole-resistant isolates. | Aspergillus salvage or selected combination use. | No useful Cryptococcus or Mucorales activity. Trichosporon is another important gap. |
| Polyene: liposomal amphotericin B (AmBisome) | Candida and Cryptococcus treatment roles. | Aspergillus and Mucorales activity. | A. terreus commonly has amphotericin resistance; rare molds need species-specific evaluation. |
| Antimetabolite: flucytosine (Ancobon) | Selected Candida and Cryptococcus treatment, usually in combination. | Not a broad mold drug. | Do not use as routine monotherapy. |
Azole spectrum
Azoles are listed by first U.S. approval year. Later agents retain yeast activity while adding coverage of some molds. Species, resistance, and the clinical indication determine which drug is appropriate.
Green Established activity or a usual clinical role in the specified setting. Amber Alternative/salvage use, reduced effectiveness, or limited clinical evidence. Red Absent or unreliable coverage. These are expected patterns and clinical roles, not the patient’s susceptibility result or a ranking of treatments. *See the organism-specific notes below.
Cryptococcus: fluconazole has established roles in selected pulmonary disease and in consolidation/maintenance after appropriate induction. CNS or disseminated disease usually requires an amphotericin-based induction regimen with flucytosine. Itraconazole is an inferior consolidation alternative; voriconazole, posaconazole, and isavuconazole are selected alternatives or salvage agents with much less evidence. [37] [38]
Suspected invasive mold disease while receiving voriconazole prophylaxis requires consideration of Mucorales, resistant Aspergillus, inadequate exposure, and other molds. Increasing the voriconazole dose does not add Mucorales activity. Aspergillus azole resistance may affect several agents; susceptibility testing should guide a change within the class.
Azole activity against endemic fungi
Disseminated histoplasmosis in HIV
Azole selection differs among Histoplasma, Blastomyces, and Coccidioides. The table applies when treatment is indicated. Severe disease may require amphotericin induction.
Itraconazole is the preferred azole for histoplasmosis
When an azole is indicated, itraconazole is preferred. For severe histoplasmosis, whether acute pulmonary or disseminated, IDSA favors liposomal amphotericin B for induction and itraconazole after clinical improvement. NIH lists voriconazole as an alternative for selected, moderately ill people with HIV who cannot tolerate itraconazole. [12] [39]
In a small retrospective cohort, initial azole treatment with voriconazole was associated with higher early mortality than itraconazole. See the fellow discussion of the cohort. [56]
Authorship disclosure: Michael Joshua Hendrix, MD, was first author of the cited retrospective cohort. [56]
Treatment considerations
Coccidioides: fluconazole is standard initial therapy for most adults with coccidioidal meningitis. For newly presenting coccidioidal meningitis in the first trimester of pregnancy, IDSA recommends intrathecal amphotericin B and specialist management. Intravenous amphotericin B has a separate role in initial nonmeningeal disease in the first trimester. Itraconazole has established roles in selected nonmeningeal disease. Voriconazole, posaconazole, and isavuconazole have alternative or salvage experience. The fluconazole mold gap in the first table refers to molds such as Aspergillus and Mucorales, not to absence of activity against Coccidioides. [41] [42]
Fellow teaching Dematiaceous molds
Candida species and susceptibility
Species are grouped by usual fluconazole susceptibility, followed by C. auris. Individual isolates may differ. Use the reported susceptibility category and infection site to guide treatment; SDD means susceptible-dose dependent.
| Species | Azoles, especially fluconazole | Echinocandins | Amphotericin B |
|---|---|---|---|
| Usually fluconazole susceptible; acquired resistance remains possible | |||
| C. albicans | Usually fluconazole susceptible; confirm the isolate. | Usually active. | Usually active; toxicity often favors other options. |
| C. tropicalis | Often susceptible, but azole resistance varies by region and exposure. | Usually active; acquired resistance is possible. | Usually active. |
| C. parapsilosis | Often susceptible historically, but resistant strains and outbreaks are increasingly reported. | Higher baseline MICs than many Candida species; this is not automatic clinical resistance. | Usually active. |
| C. lusitaniae | May be active; acquired resistance can occur. | Often active; acquired resistance can occur. | Can develop amphotericin resistance during therapy. Repeat susceptibility testing if infection persists. |
| Reduced fluconazole susceptibility: SDD or resistant, depending on the isolate | |||
| C. glabrata Nakaseomyces glabratus | Reduced susceptibility/resistance is common. High-dose fluconazole step-down only when the MIC category supports it. | Usual initial invasive-infection choice, but acquired FKS resistance can occur. | Potential option for resistant isolates; confirm susceptibility. |
| Intrinsic fluconazole resistance | |||
| C. krusei Pichia kudriavzevii | Intrinsic fluconazole resistance does not mean resistance to every azole. Voriconazole can be selected step-down therapy. | Usually active. | Clinical alternative; review susceptibility rather than assuming all isolates are susceptible. |
| Frequent fluconazole resistance; possible resistance to multiple classes | |||
| C. auris Candidozyma auris | Fluconazole resistance is common. Resistance can involve multiple drug classes; resistance may extend to newer azoles. | Usual initial adult therapy. Echinocandin resistance and pan-resistance occur. | Variable susceptibility; selected alternative for echinocandin resistance or clinical nonresponse. |
Fellow teaching Species and MIC interpretation
For adults with candidemia without organ involvement, the 2025 global guideline supports considering oral step-down after at least five days of echinocandin therapy. Confirm hemodynamic stability, documented bloodstream clearance, absence of neutropenia, source control, oral azole tolerance, and susceptibility to the planned agent. [1] [57]
Candida auris
For invasive C. auris infection in adults, an echinocandin is the usual initial choice. Demonstrated echinocandin resistance, or lack of improvement after five days of treatment, makes liposomal amphotericin B an alternative. Earlier deterioration still warrants prompt review of the diagnosis, susceptibility and source control. Pan-resistant infection requires specialist and reference-laboratory input; investigational access may be necessary. [45]
Do not treat asymptomatic colonization or attempt antifungal decolonization. Notify infection prevention and public health promptly. In acute care use Contact Precautions, clean shared equipment, and use an EPA List P disinfectant. Communicate status on transfer. Clearing an infection does not mean colonization has cleared. [48] [47]
Fellow teaching C. auris susceptibility thresholds
Azole administration and adverse effects
Pregnancy changes systemic antifungal selection. The fluconazole label describes fetal risk with prolonged high-dose exposure in the first trimester. Voriconazole and posaconazole labels also warn of fetal harm. When treatment is needed, the fungal syndrome and trimester determine whether an amphotericin B regimen is appropriate, with infectious diseases and obstetric input. [4] [6] [7] [12] [41]
Fluconazole / Diflucan
Fluconazole is well absorbed orally and reaches urine and CSF. Reliable absorption can make the oral route useful when the organism and syndrome are appropriate. Renal clearance affects maintenance exposure.
Nausea and headache are common. Watch liver injury and QT prolongation. Less common effects include severe skin reactions, reversible alopecia with prolonged treatment, and reported adrenal insufficiency. Warfarin and other CYP substrates still require review. [4]
Itraconazole / Sporanox; SUBA formulation / Tolsura
Conventional capsules depend on food and gastric acidity. Solution is better absorbed fasting. SUBA formulations have different dosing and administration instructions. They are not interchangeable milligram for milligram.
GI intolerance and liver injury can occur. Negative inotropic effects can cause edema or heart failure. Peripheral neuropathy, hearing loss, and pseudohyperaldosteronism are additional reported toxicities. New dyspnea or edema warrants prompt assessment for heart failure. If signs or symptoms of heart failure develop on conventional SPORANOX capsules, discontinue the capsules; a serum level in range does not rule out this toxicity. [5] [3]
Voriconazole / Vfend
Food changes voriconazole exposure; the oral product is taken at least an hour before or after a meal. Variable CYP2C19 metabolism and nonlinear kinetics make TDM central to treatment.
Transient visual changes are common. Hallucinations or encephalopathy may reflect excessive exposure. Also watch liver injury and QT prolongation. Prolonged treatment is associated with photosensitivity, cutaneous malignancy, and fluoride-associated periostitis. Bone pain with elevated alkaline phosphatase should prompt consideration of periostitis. Recommend sun protection and skin surveillance during prolonged treatment. [6]
Posaconazole / Noxafil
Conventional posaconazole suspension is food- and gastric-condition dependent. Exposure is generally more predictable with the delayed-release tablet or IV formulation. The conventional suspension must not be substituted for the delayed-release tablet or the delayed-release oral suspension using the same regimen.
GI effects, liver injury, and QT prolongation occur. Hypertension plus hypokalemia can represent pseudohyperaldosteronism, often with low renin and aldosterone. Check BP, potassium, and posaconazole levels; reassess the antifungal if pseudohyperaldosteronism is suspected. [7] [35]
Isavuconazonium / Cresemba
The label gives two mass values for the same product: 372 mg of isavuconazonium sulfate corresponds to 200 mg of active isavuconazole. The number changes because the names refer to different chemical forms; the vial contents have not changed. Oral absorption is reliable and not materially food dependent; IV does not require cyclodextrin.
It shortens QT and is contraindicated in familial short-QT syndrome. GI symptoms and liver abnormalities occur; serious hypersensitivity is possible. Its interaction profile differs from voriconazole’s. Strong CYP3A4 inhibitors and strong CYP3A4 inducers are contraindicated with isavuconazonium. [8] [20]
Oral voriconazole does not require renal dose reduction. IV voriconazole and IV posaconazole contain SBECD, which can accumulate in renal impairment. Product labels favor avoiding these IV formulations below the specified renal threshold unless benefit outweighs risk. Consider oral therapy and monitor renal function. [6] [7]
Echinocandins, including micafungin
Blood-culture clearance · Source control in bloodstream infection
Micafungin is IV only. It usually needs neither renal nor hepatic dose adjustment under U.S. labeling, and no dialysis replacement dose. It has fewer CYP interactions than azoles; review concomitant medications. Routine drug levels are not standard. [9]
An echinocandin is a usual initial choice for adult candidemia. For selected non-neutropenic adults, an oral switch after initial therapy is supported when blood cultures have cleared, the patient is stable, the source is controlled, the isolate is susceptible, and an oral azole can be tolerated. A positive follow-up culture makes an intravascular or other uncontrolled focus a more immediate question than an oral switch. [1] [57]
Micafungin has poor urinary, CSF, and vitreous exposure. See the urinary decision table for the distinction between collecting-system infection and hematogenous renal infection.
Adverse effects include GI symptoms and liver test abnormalities. Infusion reactions can cause rash, flushing, or hypotension. Rare serious effects include hemolysis, hepatic failure, renal injury, and anaphylaxis. Monitor liver and renal function during treatment. [9]
Fellow teaching Echinocandin resistance
Amphotericin B formulations and adverse effects
The name “amphotericin B” alone does not identify the product. Liposomal amphotericin B, amphotericin B lipid complex, and deoxycholate differ in distribution, toxicity, and dosing. They must not be interchanged milligram for milligram. Liposomal therapy lowers, but does not eliminate, renal and infusion toxicity. [10]
Creatinine, potassium, magnesium, blood counts, and liver tests help detect amphotericin toxicity. Unstable renal function or substantial electrolyte losses warrant prompt reassessment; a fixed testing or replacement schedule does not fit every patient. If separate saline hydration is appropriate, it is not the drug diluent. U.S. AmBisome is reconstituted with sterile water for injection without bacteriostatic agent and diluted with 5% dextrose. Do not reconstitute or dilute AmBisome with saline. [10]
Common problems include AKI, potassium/magnesium wasting, infusion fever or rigors, and anemia. Less common serious events include hypersensitivity, chest/back pain during infusion, and arrhythmias, including those promoted by electrolyte disturbances. Severe anaphylaxis requires immediate discontinuation of the infusion; the patient must not receive further AmBisome infusions. Unexpected phosphate elevation with AmBisome may be assay interference. [10]
Amphotericin formulation matters for urinary infection. See the urinary exposure table; liposomal amphotericin is not a substitute for deoxycholate in this setting.
Flucytosine / Ancobon
Flucytosine reaches the CNS and is usually paired with another antifungal during induction because resistance can develop on monotherapy. Known complete DPD (dihydropyrimidine dehydrogenase) deficiency is a contraindication because fluorouracil-related toxicity can be severe. Renal impairment or dialysis alters clearance. Falling kidney function during amphotericin treatment can raise flucytosine exposure, increasing marrow and liver toxicity; GI intolerance is also common. Blood counts, renal and liver function, and drug concentrations help distinguish accumulation from treatment failure. [11]
CNS penetration
HIV-associated cryptococcal meningitis treatment
CNS selection depends on the organism, clinical evidence, and drug exposure. CSF concentrations and brain tissue concentrations may differ.
| Drug | Size / binding | CNS finding | Practical interpretation |
|---|---|---|---|
| Fluconazole | Small, about 306 Da; relatively water soluble; about 11-12% bound. | CSF approximately 80% of plasma in fungal meningitis. | No Aspergillus activity despite good CSF exposure. |
| Voriconazole | Small, about 349 Da; about 58% bound. | Human CSF/plasma median 0.46 in a small PK study; brain entry demonstrated. | Established preferred azole for CNS aspergillosis when the organism is susceptible. |
| Itraconazole | Large, about 706 Da; lipophilic; 99.8% bound. | Low CSF concentrations despite substantial tissue distribution. | Do not substitute for voriconazole in CNS aspergillosis on spectrum alone. |
| Posaconazole | Large, about 701 Da; lipophilic; >98% bound. | CSF exposure often low and variable. | Selected CNS salvage use needs organism, exposure, and clinical evidence; serum levels do not directly measure brain exposure. |
| Isavuconazole | Active drug is smaller than itraconazole/posaconazole; >99% bound. | Brain tissue exposure has been demonstrated despite limited CSF exposure. | Potential CNS use is organism-specific; human evidence is much smaller than for voriconazole in CNS aspergillosis. |
[4] [6] [5] [7] [8] [15] [16] [17] [18]
Fellow teaching See molecular structures and the pharmacology behind these differences.
Fellow teaching CSF versus brain tissue
Candiduria and urinary drug concentrations
Candiduria alone does not establish infection. Asymptomatic candiduria usually needs risk-factor and catheter management, not an antifungal. IDSA exceptions include neutropenia, very low-birth-weight infants, and planned urologic manipulation. Diabetes or a chronic catheter alone is not an indication to treat. CDC advises against antifungal treatment for C. auris detected in urine without signs or symptoms of infection. Follow applicable infection prevention and reporting guidance. [1] [45] [47]
| Presentation | Treatment decision |
|---|---|
| Asymptomatic candiduria | Without a high-risk exception, an unnecessary urinary catheter is a reason to address the device, not to treat the culture. |
| Compatible cystitis symptoms | Exclude other causes. If the Candida isolate is fluconazole susceptible, fluconazole is the usual preferred drug. |
| Ascending pyelonephritis or obstructed collecting system | An active drug must reach the collecting system. Obstruction requires relief; a stent, nephrostomy, or fungus ball may also require intervention. |
| Candidemia with hematogenous renal involvement | Treat invasive candidiasis. Micafungin can remain appropriate because renal tissue exposure differs from drug concentration in urine. |
In catheterized patients, pyuria and colony count cannot reliably distinguish colonization from infection. Unexplained systemic illness, obstruction, or persistent compatible symptoms may warrant further evaluation and imaging. [1]
Antifungal concentrations in urine
| Drug | Urinary exposure | Practical consequence |
|---|---|---|
| Fluconazole | High active-drug concentrations. | Preferred for susceptible Candida urinary infection; adjust maintenance dosing for renal function. |
| Micafungin and other echinocandins | Very poor active-drug excretion into urine. | Not routine therapy for Candida cystitis or ascending collecting-system infection. Hematogenous renal infection is a different setting. |
| Voriconazole, itraconazole, posaconazole, isavuconazole | Low active-drug urinary exposure. | Do not select a mold-active azole for Candida cystitis simply because the isolate appears susceptible. |
| Amphotericin B deoxycholate | Useful urinary concentrations. | Selected resistant Candida urinary infections; substantial toxicity limits use. |
| Liposomal amphotericin B and other lipid formulations | Inadequate urinary concentrations for routine Candida UTI treatment. | Not interchangeable with deoxycholate for this indication. |
| Flucytosine | High active-drug urinary concentrations. | Flucytosine alone is an option for selected symptomatic fluconazole-resistant C. glabrata cystitis. Evidence for monotherapy in ascending pyelonephritis is weaker. Neither exception establishes monotherapy for candidemia or cryptococcosis. It is unreliable for C. krusei; renal accumulation, marrow toxicity, and resistance constrain use. |
Why the formulation and indication change exposure
An adult regimen depends on the infection, route, exact product, and organ function. The examples below explain why seemingly similar regimens are not interchangeable. The linked prescribing information and syndrome guidance give the complete schedules and adjustments.
| Clinical situation | Why the regimen differs |
|---|---|
| Starting an echinocandin for candidemia | The standard initial adult candidemia regimens for caspofungin and anidulafungin include a loading dose; micafungin does not require one. A regimen studied for candidemia does not automatically apply to endocarditis or esophageal candidiasis. [1] |
| Oral or IV azole therapy | Fluconazole maintenance exposure depends on renal function. Oral and IV voriconazole have different regimens, and changing route does not remove the need to interpret the drug concentration. Conventional posaconazole suspension and delayed-release products are not interchangeable. [3] [4] [6] [7] |
| Reading an isavuconazonium label | Isavuconazonium sulfate is the prodrug; isavuconazole is the active moiety. The amount reported for one cannot be substituted milligram for milligram for the other. [8] |
| Choosing an amphotericin B product | Liposomal amphotericin B, amphotericin B lipid complex, and deoxycholate are different products. They differ in exposure, toxicity, and preparation. A regimen for invasive mucormycosis, including CNS disease, does not establish the formulation needed for a collecting-system Candida infection. [1] [10] [19] |
| Flucytosine during renal dysfunction | Renal deterioration, including during amphotericin therapy, can produce flucytosine accumulation and marrow toxicity. Renal function, dialysis timing, blood counts, liver tests, and measured exposure inform specialist adjustment. Known complete DPD deficiency is a contraindication. [11] [14] |
Toxicity monitoring and interactions
Outpatient laboratory monitoring and result ownership
The monitoring plan follows the likely toxicity. For amphotericin, kidney injury and potassium or magnesium losses can develop together. For flucytosine, a change in renal function can quickly raise exposure and worsen cytopenias or liver injury. With azoles, baseline liver tests, interacting medicines, electrolyte abnormalities, and QT risk guide follow-up. Voriconazole labeling specifies transaminases and bilirubin at least weekly for the first month, with monthly testing thereafter if stable. Blood pressure and potassium help identify mineralocorticoid effects with posaconazole or itraconazole. [6] [7] [10] [11]
Why an interaction can reappear when an azole stops
An azole can raise exposure to a calcineurin or mTOR inhibitor, anticoagulant, vinca alkaloid, targeted cancer drug, statin, or sedative. The specific pair matters: some combinations are contraindicated, while others need drug-level or toxicity monitoring. Conversely, a potent inducer such as a rifamycin can lower exposure to certain azoles. When the azole stops, concentrations of a companion drug that was adjusted during treatment can fall again. [3]
Therapeutic drug monitoring
A concentration is interpretable only with the indication, the assay, the time of the last dose and blood draw, the formulation, and recent changes in absorption, dosing or interacting drugs. mg/L and mcg/mL are numerically equivalent. A result drawn at the wrong time can be misleading even when the number looks familiar. [14]
| Drug | Usual first assessment | Interpretation |
|---|---|---|
| Voriconazole | A trough at about day 3-5 after loading is common; earlier day 2-3 assessment is possible. | Measure the parent drug. Common treatment targets are >1-2 mg/L with an upper boundary around 5-5.5 mg/L; severe/CNS disease often prompts a higher minimum within the range. Targets vary by protocol. |
| Itraconazole | With a loading regimen, an early trough may be assessed around days 5–7; without loading, around days 10–14. For severe histoplasmosis, the suggested assessment is after 1–2 weeks. | For severe histoplasmosis, the suggested random level is 1–4 mg/L of parent itraconazole measured by chromatography. For mild or moderate acute pulmonary histoplasmosis when treated, a parent trough above 1 mg/L and below the 3–4 mg/L upper range is associated with response and lower toxicity risk. A measured sum of itraconazole plus hydroxyitraconazole has a different interpretation. For aspergillosis, some experts use a combined trough above 1–2 mg/L for treatment, with an upper boundary below 5 mg/L. A histoplasmosis parent-only target cannot be applied to that sum. [3] [12] |
| Posaconazole | A trough at about day 5-7 after loading. | A commonly used prophylaxis target is at least 0.7 mg/L. Treatment targets are commonly >1-1.25 mg/L. An upper safety boundary is less settled; high exposure should prompt toxicity review. |
| Isavuconazole | Selective TDM, particularly unexpected failure/toxicity, absorption concerns, or unusual PK. | No universally validated therapeutic window. Some centers use routine levels; others do not. Do not import voriconazole targets. |
| Flucytosine | For oral flucytosine, a 2-hour post-dose sample estimates peak exposure. Early measurement within the first 72 hours and reassessment after changes in renal function help detect accumulation. | The cited peak range of 50–100 mg/L is chiefly a toxicity-monitoring reference. Peaks above 100 mg/L are associated with greater marrow toxicity. A trough or a sample drawn at another time cannot be compared directly with this range. |
| Fluconazole, echinocandins, amphotericin B | No routine TDM for standard use. | Clinical response and organ/toxicity monitoring remain essential. |
Itraconazole and hydroxyitraconazole levels
A chromatographic assay reports itraconazole 0.7 mg/L and hydroxyitraconazole 1.3 mg/L. Their sum is 2.0 mg/L, but the parent concentration is still 0.7 mg/L. A combined value cannot be compared with a parent-only target. For histoplasmosis, a universal combined cutoff has not been established; this arithmetic alone does not establish adequate exposure. [12]
Voriconazole N-oxide has minimal antifungal activity and is not added to the voriconazole trough to determine treatment exposure. [6] [13]
Fellow teaching Itraconazole assay targets
Clinical cases
Case 1. Candida in blood and urine
A critically ill patient has candidemia and candiduria. Is micafungin inadequate because it has low urine levels?
No. Micafungin is a usual initial choice for critically ill adults with candidemia. If Candida reached the kidney through the blood, renal tissue exposure matters more than urine levels. A symptomatic ascending infection with obstruction is different: it requires a urine-active agent and relief of the obstruction. A positive urine culture alone does not establish either syndrome. [1]
Case 2. Hallucinations during voriconazole treatment
A patient develops hallucinations on day 6 after the voriconazole dose was increased. What should be checked?
Voriconazole exposure can rise disproportionately after a dose increase. Hallucinations warrant prompt assessment of the drug history, interactions, liver function, electrolytes, and a correctly timed concentration, alongside other causes of encephalopathy. Serious toxicity can require interruption or a change in therapy before the level returns. [6]
Case 3. A therapeutic level with new edema
A patient taking conventional itraconazole capsules develops new edema and dyspnea. The laboratory reports a combined itraconazole and hydroxyitraconazole level within its reference range. Does that exclude heart failure?
No. Itraconazole can impair cardiac contractility even when the reported level is in range. Discontinue conventional SPORANOX capsules if signs or symptoms of heart failure develop and evaluate promptly. Interacting calcium channel blockers and other causes of edema or dyspnea also merit review. [5]
Rounds sheet
Before the first dose
Which organism and infected site explain the illness? Source control, product and route, organ function, interacting drugs, and responsibility for follow-up determine whether an active drug is a workable choice.
Coverage gaps
Fluconazole: no Aspergillus/Mucorales, but active against Cryptococcus and Coccidioides. Itraconazole: usual Histo/Blasto azole. Voriconazole: no Mucorales. Dematiaceous molds: species-dependent.
Adverse effects
New heart-failure signs or symptoms on conventional SPORANOX capsules: discontinue and assess promptly, even with a level in range. Voriconazole can cause neurologic, visual, QT, skin and bone toxicity. Posaconazole can cause hypertension with hypokalemia. Isavuconazonium is contraindicated in familial short-QT syndrome. In pregnancy, systemic azole exposure, trimester, and fungal syndrome can change the preferred agent and route. [4] [6] [7] [41]
Amphotericin plan
Amphotericin formulations are not interchangeable. Monitor kidney function, K, Mg, blood counts and liver tests. Saline hydration, if appropriate, is separate from AmBisome preparation: never reconstitute or dilute AmBisome with saline.
TDM calculation
A parent-only itraconazole range does not apply to a combined parent-plus-hydroxy level. Voriconazole uses the parent level. A flucytosine oral peak is timed about two hours after a dose; known complete DPD deficiency is a contraindication to flucytosine.
Site of infection
CSF is not a brain tissue level. Candiduria often needs no antifungal. Micafungin has poor urine exposure; renal tissue infection from candidemia is different.
The full lecture explains assay targets and formulation exceptions. Product labeling and syndrome guidance provide complete regimens.
Fellow extension and advanced reference
Fellow extensionThe resident core and rounds sheet end above. Continue here for chemical structures, detailed interpretation, evidence, and newer agents.
Azole structures and pharmacokinetics
The triazole ring is the shared pharmacophore. Substituents around that ring change binding to fungal CYP51, lipophilicity, molecular size, protein binding, metabolism, and interactions. These changes can expand antifungal activity without improving CNS exposure.
Small size and a substantial unbound fraction favor access to fluid compartments. Lipophilicity can favor membrane passage and tissue partitioning, but very high lipophilicity can accompany extensive protein binding and low CSF concentrations. Efflux, ionization, inflammation, and the measured compartment also matter. Structure alone does not reliably predict CNS exposure.
Triazole rings and side chains
Blue marks 1,2,4-triazol-1-yl rings of the type that can coordinate the heme iron of fungal CYP51. Amber marks other ring systems, including the triazolone rings of itraconazole and posaconazole. Unhighlighted atoms and linkers also contribute to the side chains. The colors mark structural regions, not polarity. The drawings are not to scale.
Fluconazole 306.27 Da
Voriconazole 349.31 Da
Itraconazole 705.6 Da
Scroll to see the full structure.
Posaconazole 700.8 Da
Scroll to see the full structure.
Isavuconazole 437.5 Da
Advanced clinical considerations
Species-specific susceptibility interpretation
For C. glabrata, CLSI fluconazole results use susceptible-dose dependent or resistant categories rather than a standard susceptible category. A susceptible-dose dependent result requires an appropriate dose and exposure. Prior echinocandin treatment or persistent infection should prompt echinocandin testing and repeat evaluation for resistance. For C. parapsilosis, use species-specific interpretation: a naturally higher MIC does not by itself mean an echinocandin will fail. [1]
C. auris susceptibility thresholds
CDC's tentative resistance thresholds include fluconazole MIC at least 32 mg/L, amphotericin B at least 2 mg/L, and micafungin at least 4 mg/L. They are interim guides with uncertain outcome correlation, not universal susceptible breakpoints. The October 2026 CDC page notes an established CLSI C. auris-specific rezafungin breakpoint, in addition to the tentative thresholds for other agents. Ask the laboratory which method and interpretive standard it uses; do not transfer thresholds between drugs or methods. [46]
Dematiaceous molds
Melanized molds such as Alternaria, Curvularia, Exophiala, and Cladophialophora differ in susceptibility, syndrome, and optimal therapy. Itraconazole, voriconazole, and posaconazole have activity against many species, with species-specific variation. Isavuconazole has variable in vitro activity with less clinical evidence; fluconazole is unreliable. CNS disease requires attention to penetration, species identification, susceptibility results, and surgical source control. Isavuconazole susceptibility cannot be inferred from results for voriconazole or posaconazole. [43] [44]
The VITAL cryptococcosis/endemic-fungus subset included only 38 patients across five genera and had no randomized comparator. Comparative efficacy for each organism remains uncertain. [42]
Echinocandin resistance
FKS mutations can confer class resistance. Prior echinocandin exposure, persistent candidemia, and species identification affect the need for susceptibility testing. C. parapsilosis has higher baseline echinocandin MICs, but that alone does not establish treatment failure. Request susceptibility data and interpret the breakpoint for that species and drug. [1]
CSF and brain tissue concentrations
Meningitis, an angioinvasive lesion, and an encapsulated abscess are different compartments. Isavuconazole tissue measurements from two patients showed substantially different concentrations in inflamed versus normal brain. Amphotericin B can be effective in CNS infection despite low CSF levels. A concentration in homogenized tissue does not establish free extracellular exposure or comparative clinical efficacy. [16] [1]
Parent-only and combined itraconazole targets
The clinical question determines which itraconazole result to interpret. For severe histoplasmosis, the suggested 1–4 mg/L range is for parent drug measured by chromatography after 1–2 weeks; a random sample is acceptable. For mild or moderate acute pulmonary disease treated with itraconazole, the cited parent trough is above 1 mg/L and below the 3–4 mg/L upper range. Prior observations that a combined concentration above 2 mg/L may produce a similar response do not validate 2 mg/L as a universal cutoff. For aspergillosis, some experts interpret combined parent-plus-hydroxy troughs. The assay, clinical response, and toxicity remain essential. [3] [12] [13]
Key studies
Voriconazole versus itraconazole in histoplasmosis
A single-center retrospective cohort compared 175 itraconazole-treated patients with 19 voriconazole-treated patients. Voriconazole was associated with higher mortality during the first 42 days after treatment initiation (adjusted hazard ratio 4.30; 95% CI 1.3-13.9). The small voriconazole group, nonrandomized treatment assignment, and potential residual confounding limit causal inference. Use the guideline preference for itraconazole to guide agent selection and the cohort as supporting observational evidence. [56]
Isavuconazole versus voriconazole: SECURE
Day-42 mortality was 19% with isavuconazole versus 20% with voriconazole, meeting noninferiority. Drug-related adverse events were less frequent with isavuconazole. The trial did not establish superiority or equivalence for every rare mold or CNS infection. [20]
Posaconazole for primary invasive aspergillosis treatment
The 2021 randomized trial met noninferiority versus voriconazole for primary invasive aspergillosis treatment. Day-42 mortality was 15% with posaconazole versus 21% with voriconazole in the intention-to-treat population and 19% in both groups among participants with proven or probable invasive aspergillosis (31 of 163 versus 32 of 171). The confidence intervals for both treatment differences included zero. The regimen used modern IV/tablet formulations, not conventional suspension. [21]
Voriconazole TDM trials
A 110-patient single-center randomized study supported voriconazole TDM, with less discontinuation from toxicity and better treatment response. A later multicenter cluster randomized crossover study did not show improved treatment outcomes with TDM-guided dosing. PK variability and exposure-related toxicity support monitoring, although a consistent survival benefit has not been shown. [22] [23]
Breakthrough fungal infection
Confirm infection and seek species identification, histopathology, and susceptibility testing when feasible. Review adherence, formulation, absorption, interactions, achieved exposure, devices, drainage, immune recovery, and whether a second fungus lies outside the current spectrum. Persistent infection may reflect inadequate source control despite a low MIC. [2]
MIC interpretation across drug classes
Breakpoints depend on organism, method, drug exposure, and available outcomes. An epidemiological cutoff identifies a non-wild-type population; it is not a clinical susceptible breakpoint. For Aspergillus tested against echinocandins, laboratories often assess minimum effective concentration rather than the same MIC endpoint used for azoles. MIC values cannot be compared directly across classes to rank clinical efficacy. [2]
Hypoalbuminemia, obesity, critical illness, ECMO, and impaired absorption can complicate interpretation of total plasma levels. Review dosing and level interpretation with pharmacy when these factors are present. [3]
Newer experimental posaconazole data show that infection alters cerebral diffusion. These animal data do not establish a human CNS dose or clinical equivalence to voriconazole. [36]
Newer approved antifungals
| Drug / mechanism | Established U.S. role | Nuance and pitfall |
|---|---|---|
| Rezafungin / Rezzayo Long-acting echinocandin | Once-weekly IV therapy for candidemia or invasive candidiasis in adults and patients aged 12 years or older with limited or no alternatives. | Same class gaps and possible FKS cross-resistance. Not studied for Candida endocarditis, osteomyelitis, or meningitis; safety beyond four weekly doses has not been established. This is a limit of the available safety data, not a treatment duration. Infusion reactions, liver effects, and photosensitivity require attention. |
| Ibrexafungerp / Brexafemme Oral triterpenoid glucan-synthase inhibitor | Vulvovaginal candidiasis and reduction of recurrent VVC. | It is not approved for candidemia step-down. GI effects and CYP3A interactions matter. Pregnancy is contraindicated because of embryo-fetal toxicity. Verify availability separately from approval. |
| Oteseconazole / Vivjoa Tetrazole CYP51 inhibitor | Reduction of recurrent VVC in females who are not of reproductive potential. | Not a systemic mold or candidemia treatment. Contraindicated in females of reproductive potential, pregnancy, and lactation; prolonged exposure underlies the restriction. Drug interactions still require review. |
Investigational antifungals
Development status was reviewed October 14, 2026. These agents remain investigational; in vitro activity and sponsor announcements have limited clinical applicability.
| Agent | Target / route | Potential spectrum and gaps | Current evidence and status |
|---|---|---|---|
| Olorofim | Orotomide; inhibits fungal dihydroorotate dehydrogenase, blocking pyrimidine synthesis. Oral development. | Aspergillus, including some azole-resistant isolates, and selected difficult molds such as Scedosporium and Lomentospora. No useful Candida or Mucorales coverage. | Investigational. OASIS phase 3 topline results were announced in June 2026; the October 6 sponsor statement still says it is unapproved. Full published results and regulatory review are needed to define its role. |
| Fosmanogepix → manogepix | Prodrug of a Gwt1 inhibitor affecting GPI-anchored protein maturation; IV and oral development. | Broad investigational yeast and mold activity, including many resistant isolates. Important gaps include poor activity against C. krusei and related species; Mucorales activity is inconsistent. | Small single-arm phase 2 studies reported clinical activity in candidemia and mold infections; comparative efficacy is not established. Two phase 3 programs for invasive yeast and mold infections were ongoing in the 2026 sponsor update. No established routine clinical TDM target or licensed regimen. |
| Opelconazole | Inhaled triazole designed for lung exposure. | Local Aspergillus-directed development; inhalation does not establish adequate systemic or CNS therapy. | Opera-T phase 3 in refractory pulmonary aspergillosis was terminated January 7, 2026. Sponsor interim analysis reported numerically worse response and higher mortality in the active arm. The unfavorable interim findings limit its proposed clinical role. |
[27] [28] [29] [30] [31] [32] [33] [34]
New mechanisms and resistance
Olorofim is not an azole, and fosmanogepix is not an echinocandin. A new target may retain activity against isolates resistant to older classes. Spectrum, clinical efficacy, and emergence of resistance still require study. Assess the enrolled organisms, comparator, outcomes, follow-up, and safety data before applying trial results. [27] [32]
Public sources and evidence
References include public guidelines, prescribing information, clinical studies, and chemical records. Pipeline updates from sponsors are identified as such.
- Pappas et al. IDSA candidiasis guideline, 2016.
- Patterson et al. IDSA aspergillosis guideline, 2016.
- IDSA prevention of invasive aspergillosis, pharmacology appendix, 2026. TDM and formulation reference; prevention guidance is not a treatment trial.
- Diflucan prescribing information.
- Sporanox capsule prescribing information.
- Vfend prescribing information.
- Noxafil prescribing information.
- Cresemba prescribing information.
- Micafungin prescribing information.
- AmBisome prescribing information.
- Flucytosine prescribing information.
- Arnold SR, Spec A, et al. IDSA histoplasmosis guidance. Updated September 16, 2026.
- Mayo Clinic Laboratories ITCON test definition. Parent and active metabolite interpretation.
- Ashbee et al. British Society for Medical Mycology TDM guideline, 2014.
- Lutsar et al. Voriconazole concentrations in CSF and brain, 2003.
- Rouzaud et al. Isavuconazole diffusion in infected human brain, 2019. Two-patient tissue study.
- Wiederhold et al. Reference laboratory experience with azole blood and CSF concentrations, 2014.
- Barde et al. Low CNS posaconazole concentrations during cerebral phaeohyphomycosis, 2019.
- Cornely et al. Global mucormycosis guideline, 2019.
- Maertens et al. SECURE randomized noninferiority trial, 2016.
- Maertens et al. Posaconazole versus voriconazole randomized noninferiority trial, 2021.
- Park et al. Voriconazole TDM randomized trial, 2012.
- Veringa et al. Multicentre cluster randomized voriconazole TDM trial, 2023.
- Rezzayo prescribing information, revised July 2026. Indication checked October 31, 2026.
- Brexafemme prescribing information.
- Vivjoa prescribing information.
- Oliver et al. F901318 inhibits fungal DHODH, 2016.
- F2G/Shionogi OASIS phase 3 topline announcement, June 18, 2026. Sponsor report.
- F2G. IDWeek abstract acceptance and olorofim development status, October 6, 2026. Sponsor report.
- Pappas et al. Fosmanogepix candidemia phase 2 trial, 2023.
- Hodges et al. Fosmanogepix AEGIS phase 2 mold study, 2025.
- Manogepix susceptibility study, 2026. In vitro activity and important gaps.
- Basilea 2026 half-year update. Two ongoing phase 3 fosmanogepix studies; sponsor report.
- Pulmocide Opera-T phase 3 termination announcement, January 7, 2026. Sponsor report.
- Nguyen et al. Posaconazole exposure and pseudohyperaldosteronism, 2020.
- Experimental posaconazole cerebral diffusion study, 2026. Animal data, not a clinical treatment recommendation.
- Global cryptococcosis guideline, ECMM/ISHAM/ASM, 2024.
- NIH HIV opportunistic infection guidance, cryptococcosis.
- NIH HIV opportunistic infection guidance, histoplasmosis.
- IDSA blastomycosis guideline, 2008 (archived).
- IDSA coccidioidomycosis guideline, 2016.
- Isavuconazole treatment of cryptococcosis and dimorphic mycoses, VITAL subset, 2016. Nonrandomized study.
- ESCMID/ECMM systemic phaeohyphomycosis guideline, 2014.
- In vitro activities of ravuconazole and isavuconazole against dematiaceous fungi, 2020.
- CDC clinical treatment of C. auris infections. Updated November 12, 2025, and reviewed September 28, 2026.
- CDC C. auris antifungal susceptibility interpretation. Updated January 28, 2026, and reviewed October 1, 2026.
- CDC C. auris infection control guidance. Updated December 19, 2025, and reviewed September 30, 2026.
- CDC C. auris clinical overview.
- McHugh et al. Fluconazole resistance in C. parapsilosis blood isolates at a U.S. reference laboratory, 2025.
- Asner et al. Acquired multidrug resistance in C. lusitaniae during therapy, 2015.
- PubChem fluconazole compound record, CID 3365. Molecular structure source.
- PubChem voriconazole compound record, CID 71616. Molecular structure source.
- PubChem itraconazole compound record, CID 55283. Molecular structure source.
- PubChem posaconazole compound record, CID 468595. Molecular structure source.
- PubChem isavuconazole compound record, CID 6918485. Molecular structure source.
- Hendrix et al. Voriconazole versus itraconazole for the initial and step-down treatment of histoplasmosis: a retrospective cohort. Clinical Infectious Diseases, 2021;73:e3727-e3732. doi:10.1093/cid/ciaa1555.
- Cornely OA, Sprute R, et al. Global guideline for the diagnosis and management of candidiasis. ECMM, ISHAM, and ASM. Lancet Infect Dis. 2025;25:e280-e293.